2 unknown, 1 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Unknown 2, Completed 1 |
Follow Cardresearch: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial Fluvoxamine Maleate 100 MG, Placebo, Metformin Extended Release Oral Tablet - Long COVID-19 Syndrome, Chronic Fatigue Syndrome | Phase 3 | Completed | Cardresearch | 399 | 2023-10-18 | 2026-04-13 |
| Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms Spirulin Platensis, Budesonide Powder, Fluoxetine 20 MG - Covid19, SARS-Associated Coronavirus | Phase 3 | Unknown | Cardresearch | 7819 | 2021-01-19 | 2024-05-08 |
| Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: "The Hope Coalition - 1" Hydroxychloroquine Sulfate Tablets, Lopinavir/ Ritonavir Oral Tablet, Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets - COVID-19, Coronavirus Infection | Phase 3 | Unknown | Cardresearch | 1968 | 2020-06-03 | 2021-01-26 |
COVID-19 (2) · Severe Acute Respiratory Syndrome (2) · Coronavirus Infections (1) · Fatigue Syndrome, Chronic (1) · Post-Acute COVID-19 Syndrome (1) · Virus Diseases (1)
Fluvoxamine (2) · Fluoxetine (1) · Hydroxychloroquine (1) · Lopinavir (1) · Ritonavir (1)
Brazil (3)
Gilmar Reis, MD,PhD. (2) · Edward J Mills, FRCP (1) · Gilmar Reis, MD, PhD (1)
PMID 33885775, PMID 34717820, PMID 34927127, PMID 35353979, PMID 36516104, PMID 36780676, PMID 37068273, PMID 37256990, PMID 39232602, PMID 41911553, PMID 42832803